Related Experiment Videos
Heart failure and hepatitis in a patient taking tocainide
International Journal of Cardiology
|January 1, 1984
Abstract:
We report, for the first time to our knowledge, heart failure and liver abnormalities which developed after 2 months of treatment with tocainide.
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Do women newly diagnosed with breast cancer and consulting surgeon assess decision-making equally?
Breast (Edinburgh, Scotland)·2004
Representing patient preference-related concepts for inclusion in electronic health records.
Journal of biomedical informatics·2002
Developing a module for nursing documentation integrated in the electronic patient record.
Journal of clinical nursing·2002
An information system to improve financial management, resource allocation and activity planning: evaluation results.
Studies in health technology and informatics·2001
Serial high-sensitivity troponin-T and risk of heart failure in individuals with suspected acute coronary syndrome.
International journal of cardiology·2026
Ai-based multimodal analysis of ECG and clinical data for evaluation for competitive sports participation: The VALETUDO trial.
International journal of cardiology·2026
Erosion and embolization after transcatheter atrial septal defect closure: Findings from a multicenter international survey.
International journal of cardiology·2026
Endothelial dysfunction and long-term outcomes in patients with myocardial infarction and non-obstructive coronary arteries.
International journal of cardiology·2026
Feasibility of Single-Session Whole-Liver Yttrium-90 Radioembolization for Multifocal Hepatocellular Carcinoma.
Korean journal of radiology·2026
Cemiplimab in cutaneous squamous cell carcinoma: a longer follow-up study focusing on the late toxicities.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Not all anti-CD38 antibodies are created equal: The epitope of felzartamab is partially DTT-resistant.
Transfusion medicine (Oxford, England)·2026